IntegenX Announces Rapid Directional mRNA Library Preparation Kit for Next
Generation Sequencing (NGS)
PLEASANTON, Calif. -- November 06, 2012
IntegenX Inc. today announced the commercial introduction of the company’s
directional messenger RNA (mRNA) kit for automated NGS library preparation on
the Apollo 324™ System. Requiring just 500 picograms of mRNA starting
material, the new kit speeds RNA-Seq analysis of a broad range of clinical
samples including tissue collections, allowing for rapid, systematic, genetic
exploration. The new product joins an expanding IntegenX offering of DNA, RNA,
and ChIP-Seq kits for preparing sequencing libraries for analysis on popular
NGS platforms from Illumina^® (GA, HiSeq™ and MiSeq™), Life Technologies (Ion
Proton™ and Ion Torrent PGM™), and Roche (GS Junior™, GS FLX™ and GS FLX+).
The company made the announcement at the 2012 annual meeting of the American
Society of Human Genetics in San Francisco, California.
The new mRNA kit product announcement follows the recent formation of a
Sequencing Business Unit at IntegenX to handle fast-growing demand for the
Apollo 324 System and accelerate the company’s responsiveness to the NGS
community. “The Business Unit structure enables us to leverage the increasing
market acceptance of the Apollo 324 System and our expertise in nucleic acid
chemistry automation to continue leading the marketplace,” explained Stevan
Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX.
Regarding the new product introduction, Sequencing Business Unit Vice
President Tom Olenic said, “With our expanding range of kits optimized for the
Apollo 324 System, we’re proving that researchers and clinicians can take
advantage of fast, automated protocols for DNA sequencing, RNA-Seq, and
ChIP-Seq applications without the frustration and inefficiencies of
programming a robotic system. The Apollo 324 instrument finally makes it
practical to prepare samples for studies on biopsy samples in the process of
solving biological problems,” added Mr. Olenic.
About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of
rapid human DNA identification technology, next-gen sequencing library
preparation, and DNA/RNA ambient temperature stability and storage products.
IntegenX technology platforms are the result of the integration of advanced
fluidics, optics, and biochemistry capabilities to produce products for
DNA-based human identity testing and forensics, next generation sequencing and
biodefense applications. The company’s expertise and extensive intellectual
property includes its patented MOVe™ valve technology, patent-pending PrepX™
reagent kits for next generation sequencing library preparation, as well as a
portfolio of patented reagents for DNA and RNA preservation including
GenTegra^® for stabilization and storage of purified DNA and RNA, and
GenPlate^® for storage of blood samples. For more information, please visit
IntegenX, the IntegenX logo, Apollo 324, PrepX, GenTegra and GenPlate are
trademarks of IntegenX Inc. All other names and trademarks are the property of
their respective owners.
Howard D. Goldstein, 925-701-3481
Press spacebar to pause and continue. Press esc to stop.